Voltari Corp. (VLTC) Under Carl Icahn Umbrella, Dyax Corp. (DYAX) Potential Angioedema Preventive Treatment

Author's Avatar
Apr 01, 2015

03May20171131421493829102.jpgVoltari Corporation (VLTC, Financial)

The price of Voltari Corporation (VLTC, Financial) stock more than doubled in the extended session Tuesday after billionaire investor Carl Icahn (Trades, Portfolio) disclosed in a filing with the Securities and Exchange Commission that he recently acquired 4.06 million shares of VLTC at a price of $1.36.

Carl Icahn (Trades, Portfolio) now owns 4.74 million shares of VLTC, representing a 52.3% stake in the company

03May20171131421493829102.png

VLTC is a digital advertising company dedicated to helping companies get the most out of their marketing budgets and the lifetime value of their customers

More about Voltari Corporation (VLTC, Financial) at www.voltari.com

**

03May20171131421493829102.jpgDyax Corp. (DYAX, Financial)

Shares of Dyax Corp. (DYAX, Financial) soared in after-hours trading on Tuesday, after the company reported positive results from an ongoing Phase 1b clinical study designed to assess the safety, tolerability and pharmacokinetics of DX-2930 in patients with hereditary angioedema (HAE), a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx.

DYAX's DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of HAE attacks.

According to DYAX, DX-2930 was well tolerated at all dose levels, the study met all of its primary objectives, and notably, DX-2930 also demonstrated statistically significant reductions in HAE attack rate compared to placebo, an important characteristic for a prophylactic treatment.

DYAX also announced receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of DX-2930 for HAE attacks.

03May20171131431493829103.png

DYAX is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs.

More about Dyax Corp. (DYAX, Financial) at www.dyax.com

**

03May20171131431493829103.jpgCrown Equity Holdings Inc. (CRWE, Financial)

The company is currently developing its CRWE Network (www.CRWE-PR.com), a growing network of community targeted sites.

It has recently included Merced, California (www.merced.crwe-pr.com) into the CRWE Network.

Merced, county seat of Merced County, is situated in the San Joaquin Valley of Central California. Traditionally reliant on agriculture, the city's economy also benefited from the presence of Castle Air Force Base until its closure in 1995. Industrial development is increasing in the area.

Merced had an estimated population in 2013 (U.S. Census Bureau) of 81,102, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally.

The CRWE Network has reached the 1,487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.

03May20171131431493829103.jpg

03May20171131441493829104.jpg The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE Network. It will allow people to submit their listings for exposure to visitors searching for homes.

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE, Financial) at www.crownequityholdings.com

**

Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer